Porter CD - Search Results

1

Efficient retroviral transduction of human bone marrow progenitor and long-term culture-initiating cells: partial reconstitution of cells from patients with X-linked chronic granulomatous disease by gp91-phox expression.

Porter CD, Parkar MH, Collins MK, Levinsky RJ, Kinnon C. Porter CD, et al. Blood. 1996 May 1;87(9):3722-30. Blood. 1996. PMID: 8611697 Free article.

2

p22-phox-deficient chronic granulomatous disease: reconstitution by retrovirus-mediated expression and identification of a biosynthetic intermediate of gp91-phox.

Porter CD, Parkar MH, Verhoeven AJ, Levinsky RJ, Collins MK, Kinnon C. Porter CD, et al. Blood. 1994 Oct 15;84(8):2767-75. Blood. 1994. PMID: 7919388 Free article.

3

X-linked chronic granulomatous disease: correction of NADPH oxidase defect by retrovirus-mediated expression of gp91-phox.

Porter CD, Parkar MH, Levinsky RJ, Collins MK, Kinnon C. Porter CD, et al. Blood. 1993 Oct 1;82(7):2196-202. Blood. 1993. PMID: 8400270 Free article.

4

Detection of gp91-phox precursor protein in B-cell lines from patients with X-linked chronic granulomatous disease as an indicator for mutations impairing cytochrome b558 biosynthesis.

Porter CD, Kuribayashi F, Parkar MH, Roos D, Kinnon C. Porter CD, et al. Biochem J. 1996 Apr 15;315 ( Pt 2)(Pt 2):571-5. doi: 10.1042/bj3150571. Biochem J. 1996. PMID: 8615831 Free PMC article.

5

Identification of a donor splice site mutation leading to loss of p22-phox exon 5 in autosomal chronic granulomatous disease.

Porter CD, Parkar MH, Kinnon C. Porter CD, et al. Hum Mutat. 1996;7(4):374. doi: 10.1002/humu.1380070402. Hum Mutat. 1996. PMID: 8723692 No abstract available.

6

Superoxide production by normal and chronic granulomatous disease (CGD) patient-derived EBV-transformed B cell lines measured by chemiluminescence-based assays.

Porter CD, Parkar MH, Collins MK, Levinsky RJ, Kinnon C. Porter CD, et al. J Immunol Methods. 1992 Nov 5;155(2):151-7. doi: 10.1016/0022-1759(92)90281-w. J Immunol Methods. 1992. PMID: 1331241

7

Gene therapy for X-linked immunodeficiencies.

Kinnon C, O'Reilly MA, Pelham A, Malcolm S, Porter CD, Parkar MH, Collins MK, Leveinsky RJ. Kinnon C, et al. Among authors: porter cd. Allergol Immunopathol (Madr). 1991 Jan-Feb;19(1):32-7. Allergol Immunopathol (Madr). 1991. PMID: 1683141 No abstract available.

8

Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumors.

Patel PM, Flemming CL, Fisher C, Porter CD, Thomas JM, Gore ME, Collins MK. Patel PM, et al. Among authors: porter cd. Hum Gene Ther. 1994 May;5(5):577-84. doi: 10.1089/hum.1994.5.5-577. Hum Gene Ther. 1994. PMID: 8054375

9

Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors.

Porter CD, Collins MK, Tailor CS, Parkar MH, Cosset FL, Weiss RA, Takeuchi Y. Porter CD, et al. Hum Gene Ther. 1996 May 20;7(8):913-9. doi: 10.1089/hum.1996.7.8-913. Hum Gene Ther. 1996. PMID: 8727505

10

Gene therapy for primary immunodeficiency.

Thrasher AJ, Goldman J, de Alwis M, Porter CD, Kinnon C. Thrasher AJ, et al. Among authors: porter cd. Biochem Soc Trans. 1997 May;25(2):537-40. doi: 10.1042/bst0250537. Biochem Soc Trans. 1997. PMID: 9191151 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters